# ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

## Examples

- `captopril`
- `enalapril`
- `lisinopril`
- `ramipril`
- `perindopril`
- `fosinopril`
- `trandolapril`
- `benazepril`

> ↓ afterload, ↓ preload, ↓ BP, ↓ remodeling of heart/vessels.

> Note: (most are **prodrugs**, except `captopril` and `lisinopril`)

## Mechanism of Action (MOA)

- Inhibit **angiotensin-converting enzyme (ACE)**, preventing:
  - Conversion of **angiotensin I → angiotensin II**,
  - ↓ Angiotensin II–mediated **vasoconstriction**, **aldosterone secretion**, and **sympathetic activity**.

- Also prevent **bradykinin degradation**, → ↑ bradykinin → **vasodilation** (via nitric oxide and prostacyclin).

## Pharmacodynamics

| Action                     | Effect                                                              |
| :------------------------- | :------------------------------------------------------------------ |
| **Arteriolar dilation**    | ↓ systemic vascular resistance                                      |
| **Venodilation**           | ↓ preload                                                           |
| **↓ Aldosterone**          | ↓ Na⁺ and water retention                                           |
| **↓ Sympathetic activity** | Stabilizes BP and HR                                                |
| **Cardioprotective**       | Prevents/reverses cardiac remodeling in CHF, post-MI                |
| **Renoprotective**         | Slows diabetic nephropathy progression (↓ intraglomerular pressure) |

## Pharmacokinetics

| Drug         | Prodrug? |  Onset   |   Duration    | Route | Notes                                             |
| :----------- | :------: | :------: | :-----------: | :---- | :------------------------------------------------ |
| `captopril`  |    ❌    |  Rapid   | Short (6–8 h) | Oral  | Sulfhydryl group → rash, taste disturbance        |
| `enalapril`  |    ✅    |   Slow   |     Long      | Oral  | Prodrug → `enalaprilat` (IV form for emergencies) |
| `lisinopril` |    ❌    | Moderate |  Long (24 h)  | Oral  | Not metabolized, excreted unchanged               |
| `ramipril`   |    ✅    |   Slow   |     Long      | Oral  | Once daily; cardioprotective                      |

- **Elimination:** Mainly renal (adjust dose in renal impairment except `fosinopril`).
- **Half-life:** 6–50 h depending on the drug.

## Indications

- **Primary hypertension**
- **Chronic heart failure** (systolic)
- **Post–myocardial infarction** (to prevent remodeling)
- **Diabetic nephropathy / CKD with proteinuria**
- **Left ventricular dysfunction**

## Adverse Effects

| System             | Effect                                                | Mechanism                              |
| :----------------- | :---------------------------------------------------- | :------------------------------------- |
| **Respiratory**    | **Dry cough**                                         | ↑ bradykinin                           |
| **CVS**            | Hypotension (esp. after first dose)                   | ↓ Ang II                               |
| **Renal**          | ↑ Serum creatinine, **hyperkalemia**                  | ↓ Aldosterone                          |
| **Allergic/Other** | Angioedema                                            | ↑ Bradykinin (can be life-threatening) |
| **Dermatologic**   | Rash, urticaria                                       | esp. with `captopril`                  |
| **Metabolic**      | No effect on lipid or glucose → **safe in diabetics** | —                                      |

## Cautions

- **First-dose hypotension** in volume-depleted or diuretic-treated patients.
- **Monitor K⁺ and renal function** (risk of hyperkalemia, especially with `spironolactone` or `NSAIDs`).
- **Elderly or renal impairment:** dose adjustment needed.

## Contraindications

- **Pregnancy** (teratogenic – renal malformation, fetal death)
- **Bilateral renal artery stenosis**
- **History of angioedema (ACEI-induced)**
- **Severe hyperkalemia**

## Drug Interactions

- ↑ Risk of **hyperkalemia** with potassium-sparing diuretics, K⁺ supplements, or NSAIDs.
- NSAIDs may ↓ antihypertensive effect (↓ prostaglandins).
- Additive hypotension with other antihypertensives.

## Key Point Summary

| Feature                | ACE Inhibitors                                                      |
| :--------------------- | :------------------------------------------------------------------ |
| **Primary Action**     | Inhibit Ang I → Ang II conversion; ↑ bradykinin                     |
| **Effect on BP**       | ↓ SVR (afterload), ↓ volume (preload)                               |
| **Reflex Tachycardia** | Absent (due to ↓ sympathetic tone)                                  |
| **Renal Effect**       | ↓ GFR (esp. in renal artery stenosis), but long-term renoprotective |
| **Adverse Effects**    | Cough, hyperkalemia, angioedema                                     |
| **Contraindicated In** | Pregnancy, renal artery stenosis                                    |
| **Special Use**        | CHF, post-MI, diabetic nephropathy                                  |
